Abstract: The present invention disclosed a process for the synthesis of anthranilic diamide compound of formula (I), wherein, R1, R2, R3a, R3b, R3c, R4, R5, R6 and Z are as defined in the detailed description. The process comprising the step of obtaining a mono- or dicyano substituted aniline compound of formula (IV) which is then converted to an anthranilic acid compound of formula (V) or an anthranilic amide compound of formula (Va).

Abstract: A method of treating cancer is provided. The method includes administering to a subject in need thereof an effective amount of a compound selected from the group consisting of a glycogen phosphorylase inhibitor, a glycogen synthase inhibitor, a glycogen degradation molecule, an anti-sense oligonucleotide that down-regulates glycogen synthesis, and combinations thereof, where the cancer includes elevated levels of glycogen.

Abstract: Methods for detecting the presence of proteins in a subject are described. The proteins detected can be indicative of acute myeloid leukemia (AML). The proteins can be particularly useful for monitoring minimal residual disease (MRD) in AML.

Abstract: Described herein are protein-payload conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic and/or imaging agent moieties. In certain embodiments, provided are specific and efficient methods for producing protein-payload constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and Diels-Alder techniques. Antibody-drug conjugates and compositions which comprise glutaminyl-modified antibodies, Diels-Alder adducts, and reactive payloads and are provided.

Abstract: Bimetal oxide catalyst and methods, a method comprises: mixing and grinding to obtain a mixture comprising a manganese salt (a), at least one of other metal salt (b), and an additive (c), wherein the other metal salt comprises at least one of a copper salt, a cobalt salt, a cerium salt, an iron salt, or a nickel salt, and the additive comprises at least one of polyol or organic acid, and calcining the mixture to obtain the bimetal oxide catalyst.

Abstract: The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

Abstract: The present invention provides a method for producing an aromatic nitrile compound, the method comprising a dehydration reaction wherein a desired compound can be selectively obtained with high yield while suppressing the generation of by-products during the regeneration of an aromatic amide compound into the corresponding aromatic nitrile compound. In addition, the present invention realizes a method for efficiently producing a carbonate ester by applying the abovementioned production method to a method for producing a carbonate ester. The above are achieved by means of a method for producing an aromatic nitrile compound involving a dehydration reaction wherein an aromatic amide compound is dehydrated, the method having a contact step for bringing the aromatic amide compound into contact with a catalyst in a gas phase during the dehydration reaction.

Abstract: The present invention relates to a process for preparing dioxolane by reacting ethylene glycol with an aqueous solution of formaldehyde in the presence of an acid catalyst. The raw product comprising water, dioxolane and methanol is fed to a phase separation unit (20) wherein an organic extracting agent is present. An organic fraction stream from the phase separation unit is transferred to an upper part of a purification column (30) from which dioxolane is withdrawn as a bottom product while the distillate stream of the purification column is recycled to the phase separation unit. An aqueous fraction stream from the phase separation unit is transferred to a waste water column (40), withdrawing a waste water stream from the bottom of the waste water column, recycling a distillate stream (42) from the waste water column to the phase separation unit, and withdrawing a side stream (43) containing methanol from a stage below the feed stage of the waste water column.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Abstract: The present invention relates to a process for preparing dioxolane by reacting ethylene glycol with an aqueous solution of formaldehyde in the presence of an acid catalyst. The raw product comprising water, dioxolane and methanol is fed to a phase separation unit (20) wherein an organic extracting agent is present. An organic fraction stream from the phase separation unit is transferred to an upper part of a purification column (30) from which dioxolane is withdrawn as a bottom product while the distillate stream of the purification column is recycled to the phase separation unit.

Abstract: The present invention relates to methods of treating coronavirus infections using compounds having anti-tubulin or tubulin disruption activity.

Abstract: Provided is a process for preparing a compound, comprising the steps of a) Reacting a compound of Formula A (Formula A) with the compound 3 (3) to provide the compound 5 (5) or a salt or solvate thereof, wherein R is a linear or branched C1-C5 alkyl. Further provided is the compound 5 or a salt or solvate thereof. (5) The use of these compounds in the synthesis of 3-[5-Amino-4-(3-Cyanobenzoyl)-Pyrazol-1-yl]-N-Cyclopropyl-4-Methylbenzamide is also provided.

Abstract: The invention relates to novel organic semiconducting compounds containing a polycyclic unit, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to the use of the compounds, compositions and polymer blends as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, perovskite-based solar cell (PSC) devices, organic photodetectors (OPD), organic field effect transistors (OFET) and organic light emitting diodes (OLED), and to OE, OPV, PSC, OPD, OFET and OLED devices comprising these compounds, compositions or polymer blends.

Abstract: Disclosed herein are Notch transcriptional activation complex kinase (“NACK”) inhibitors, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein include compounds of Formula (la) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

Abstract: Disclosed are a catalyst including copper (Cu) particles having specific properties as an active metal dispersed and supported on an alumina support, a method of preparing the same, and a method of hydrogenating furan-based compounds such as 5-(hydroxymethyl)furfural (HMF) derived from biomass with a high selective conversion and high efficiency using the catalyst.

Abstract: Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.

Abstract: Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).

Abstract: The present invention provides a dynamic interface system between an extraction device and a chromatographic purification device for separating and purifying substance(s) from a mixture or matrix. One embodiment is the Supercritical Fluid Interface (“SFI”) between Supercritical Fluid Extraction (“SFE”), and Supercritical Fluid Chromatography (“SFC”). The SFI is capable of interfacing; gas, subcritical and supercritical fluid extraction methods and pair with gas, subcritical and supercritical fluid chromatography technologies that operate within the pressure and temperature parameters of the SFI. The SFI can operate up to 200 degrees celsius and 5000 psi.